Axcellant

Axcellant is a European CRO specializing in sophisticated clinical trials, especially in nuclear medicine and advanced imaging. The company is currently conducting a large-scale clinical trial in the US for a novel radioactive diagnostic compound on behalf of a European client, targeting applications in oncology, cardiology, and neurology[1][3]. The trial is being conducted at approximately 20 US sites, primarily on the East Coast and Midwest, and has the potential to impact over 20 million patients in the US and 200 million worldwide[1][3]. The FDA has reviewed and approved the clinical development plan, and Axcellant is preparing to launch manufacturing sites and activate clinical centers[1][3]. The company emphasizes high-quality data, regulatory compliance, and patient safety throughout the trial process[4][7].